Literature DB >> 6668509

Survival of women with metastatic breast cancer at Yale from 1920 to 1980.

M Todd, M Shoag, E Cadman.   

Abstract

The tumor registry at Yale--New Haven Hospital, which began recording data in 1920, was utilized to examine the ultimate outcome of all breast cancer patients who were initially diagnosed at Yale with metastatic breast cancer. Of the 5,898 patients with breast cancer seen from 1920 to 1980, 574 initially had metastatic cancer. The median survival of these patients increased steadily from 21 months in 1920 to 41 months in the decade from 1970 to 1980. The percentage of women actually surviving 5 years increased from 5% in the 1920s to approximately 25% in the 1960s. Despite the use of combination drug programs in the 1970s, the percentage of these patients remaining alive at 5 years remained near 25%. Firm conclusions cannot be made from a retrospective study spanning 60 years, although the trends depicted and lack of continued improvement indicate that our current therapeutic approach to metastatic breast cancer may not result in dramatic improvement in overall survival.

Entities:  

Mesh:

Year:  1983        PMID: 6668509     DOI: 10.1200/JCO.1983.1.6.406

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.

Authors:  Stefan Buchholz; Andrew V Schally; Jörg B Engel; Florian Hohla; Elmar Heinrich; Frank Koester; Jozsef L Varga; Gabor Halmos
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-29       Impact factor: 11.205

2.  Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.

Authors:  L Rausa; A Russo; V Gebbia; N Gebbia; N D'Alessandro; S Palmeri
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Parathyroid hormone-related protein: primary osteolytic factor produced by breast tumor cells in vitro?

Authors:  A Tabuenca; S Mohan; C A Garberoglio; P I Borgen; T Rosol; T A Linkhart
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

4.  Survival effect of systemic therapy on patients developing metastatic breast carcinoma.

Authors:  J Rouesse; S Friedman; I Guash-Jordan; K Hacene; M Brunet
Journal:  Breast Cancer Res Treat       Date:  1990-01       Impact factor: 4.872

5.  Treatment of the terminal stages of breast cancer.

Authors:  K Holli; M Hakama
Journal:  BMJ       Date:  1989-01-07

6.  Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries.

Authors:  Patricia Tai; Edward Yu; Vincent Vinh-Hung; Gábor Cserni; Georges Vlastos
Journal:  BMC Cancer       Date:  2004-09-02       Impact factor: 4.430

Review 7.  Predicting survival of de novo metastatic breast cancer in Asian women: systematic review and validation study.

Authors:  Hui Miao; Mikael Hartman; Nirmala Bhoo-Pathy; Soo-Chin Lee; Nur Aishah Taib; Ern-Yu Tan; Patrick Chan; Karel G M Moons; Hoong-Seam Wong; Jeremy Goh; Siti Mastura Rahim; Cheng-Har Yip; Helena M Verkooijen
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

8.  A new statistical method for curve group analysis of longitudinal gene expression data illustrated for breast cancer in the NOWAC postgenome cohort as a proof of principle.

Authors:  Eiliv Lund; Lars Holden; Hege Bøvelstad; Sandra Plancade; Nicolle Mode; Clara-Cecilie Günther; Gregory Nuel; Jean-Christophe Thalabard; Marit Holden
Journal:  BMC Med Res Methodol       Date:  2016-03-05       Impact factor: 4.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.